Shijiazhuang Yiling Pharmaceutical Co: Revenue and profit declined sharply, but R&D and market leadership in core products remain strong

About this update from Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A

H1 2024 revenue fell 32% and net profit dropped 67% year-over-year, mainly due to lower respiratory product demand, while R&D investment and international expansion continued. Cardiovascular and respiratory products remain market leaders despite industry headwinds.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A